IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics is a commercial-stage biotechnology company that develops and delivers individualized tumor-infiltrating lymphocyte cell therapies for patients with solid tumor cancers. Its primary commercial offerings are Amtagvi, a one-time T-cell therapy for adults with advanced melanoma who have undergone prior treatments, and Proleukin, an injectable interleukin-2 medication utilized in cancer treatment regimens and cellular manufacturing. The company distributes its therapies and pharmaceutical products to specialized authorized treatment centers, healthcare professionals, commercial medicine distributors, and biomedical research institutions treating adult oncology patients.

The organization operates a centralized manufacturing site, the Iovance Cell Therapy Center, situated in Philadelphia, Pennsylvania, which possesses an annual production capacity exceeding five thousand patient treatments. To date, treatments manufactured through these proprietary processes have served more than fifteen hundred patients. Geographically, the business delivers cellular therapies across North America, Europe, and the Asia-Pacific region. Its lead product holds regulatory clearance in the United States and Canada, while its secondary product is approved domestically and licensed across multiple international markets.

Summary of the business section of Iovance Biotherapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 975 employees, 775 of whom were engaged in research and development, and commercial manufacturing activities, and 200 of whom were engaged in general and administrative support activities.”